BEGIN:VCALENDAR
PRODID:-//eluceo/ical//2.0/EN
VERSION:2.0
CALSCALE:GREGORIAN
BEGIN:VEVENT
UID:ee84e206-7524-464a-93ee-0756c49a6cfd
DTSTAMP:20261028T122438Z
SUMMARY:Advancing local therapies for glioblastoma through a multidisciplin
 ary collaboration
DESCRIPTION:<p><strong>IN-PERSON EVENT - REGISTER <a href="https://forms.of
 fice.com/e/1u73cpSfmi">HERE</a></strong><a href="https://forms.office.com/
 e/1u73cpSfmi"><strong>&nbsp\;</strong></a>to attend</p>\n<p style="text-al
 ign: justify\;">By <strong>Dr&nbsp\;Chiara Bastiancich</strong>&nbsp\;- In
 stitut de Neurophysiopathologie\, France</p>\n<p style="text-align: justif
 y\;"><strong>Abstract</strong>: Glioblastoma (GBM) remains incurable despi
 te a multimodal treatment consisting in surgery\, radiotherapy and oral ch
 emotherapy with Temozolomide (Stupp protocol). Dr. Chiara Bastiancich’s 
 current research focuses on dissecting the dynamic post-surgical microenvi
 ronment (SMe) to identify therapeutic targets and time windows for interve
 ntion. By combining advanced imaging\, immunophenotyping\, and localized n
 anomedicine-based drug delivery\, her team has shown that transient blood-
 brain barrier disruption and pro-tumoral immune activation post-surgery co
 ntribute to recurrence. Her preclinical studies demonstrate that pairing l
 ocal chemotherapy with systemic immunomodulation delays tumor regrowth and
  improves survival. This work paves the way for novel combinatory treatmen
 ts that strategically exploit the SMe to prevent GBM relapse.</p>\n<p styl
 e="text-align: justify\;"><span style="text-decoration: underline\;">Main 
 references</span> <br>1. Bastiancich et al. Advanced Drug Delivery Reviews
  177:113951 (2021)<br>2. Bianco*\, Bastiancich* et al. J Neurosci Methods.
  284:96-102 (2017)<br>3. Bastiancich et al. J Control Release 264:45-54 (2
 017)<br>4. Bastiancich et al. Nanomedicine (Lond) 13(16):1999-2013 (2018)<
 br>5. Wang et al. Drug Deliv Transl Res 14(12):3322-3338 (2024)<br>6. Bast
 iancich et al. J Exp Clin Cancer Res 43(1):311 (2024)</p>\n<p style="text-
 align: justify\;"><strong>Short Bio:&nbsp\;</strong>Dr Chiara Bastiancich 
 (PharmD/PhD/HDR) is a tenured CNRS research fellow at the Institute of Neu
 roPhysiopathology (INP\, Marseille) in the Gliomagenesis &amp\; MicroEnvir
 onment (GlioME) group. She holds a PhD in Pharmaceutical Sciences from UCL
 ouvain (Belgium) and the University of Angers (France). Her multidisciplin
 ary expertise spans pharmaceutical technology\, neuro-oncology\, and immun
 ology\, with a strong focus on translational research for malignant brain 
 tumors. She has authored over 30 peer-reviewed publications and leads coll
 aborative projects across Europe. Her research bridges nanomedicine and tu
 mor biology\, aiming to develop innovative\, localized therapies for gliob
 lastoma (GBM)\, an aggressive brain tumor with high recurrence rates. Chia
 ra has contributed by developing chemotherapeutic hydrogels to be injected
  into the post-surgical cavity to prolong survival in clinically relevant 
 murine models. Her current work investigates how surgery reshapes the brai
 n microenvironment and triggers immune responses that contribute to the on
 set of recurrence. By combining local drug delivery with systemic immunomo
 dulation\, she develops rational\, time-sensitive therapeutic strategies t
 o delay relapse.</p>\n<p style="text-align: justify\;">Hosted by <strong>I
 CREA&nbsp\;Prof. Kostas Kostaleros\,</strong> <a href="/en/nanomedicine-la
 b">Nanomedicine</a>&nbsp\;Lab Leader.<strong><br><br></strong></p>
DTSTART:20250905T093000
DTEND:20250905T215959
LOCATION:ICN2 Seminar Room\, Campus UAB
CATEGORIES:ICN2 Seminars
END:VEVENT
END:VCALENDAR